Company Performance Metrics
- Armin Giese: Chief Scientific Officer
- Torsten Matthias: Chief Executive Officer
MODAG aims to provide a novel approach for treating neurodegenerative diseases by combining targeted small molecule therapeutics with the right diagnostic tools. Their first objective is to demonstrate clinical proof-of-concept with their lead compound anle138b in Multiple System Atrophy (MSA) seeking to halt the progression and provide a first
disease-modifying therapeutic.
This success will allow us to apply their technology to similar diseases such as Parkinson’s and other synucleinopathies with the goal of dissolving disease-related intra-cellular oligomers, thereby reducing their toxic properties.
MODAG is comprised of experts in the clinical research and neurodegenerative disease space and supported by grants from leading patient organizations including the Michael J Fox Foundation, Cure Parkinson's Trust and Parkinson’s UK.
